Serum Institute’s Cervavac gets WHO prequalification
In short
Serum Institute’s HPV vaccine Cervavac received WHO prequalification.
That means U.N. agencies can buy it, and the vaccine covers four HPV types for girls and boys aged 9 to 26. The report does not say when wider orders will start or how big they may be.
What the reporting says
Serum Institute’s HPV vaccine Cervavac received WHO prequalification, allowing it to be procured by U.N. agencies, according to the publisher summary. The vaccine targets four HPV types and is indicated for girls and boys aged 9 through 26 years. The immediate consequence is broader access potential through international procurement, but the reporting does not state when sales will begin or the scale of demand.
Why it matters
Serum Institute’s Cervavac received WHO prequalification, which opens the vaccine to procurement by U.N. agencies. The publisher summary also said it targets four HPV types and is meant for girls and boys aged 9 through 26 years. The development could support wider access and sales, but the reporting does not state order size, timing, or any financial impact.